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Cross-referencing of the word quality and
Vascular Surgery in medical databases before 1985
results in titles concerned with such aspects of vas-
cular surgery as “quality of the saphenous vein as a
determinant of patency in tibial bypass.” Little men-
tion of quality related to the classic Donabedian
triad of structure, process, and outcomes was made
until the 1990s.1 Nonetheless, Vascular Surgery now
seeks the best way to combine the clinical outcomes
specific to the field with outcomes measures that
assess more difficult metrics such as independence,
self-perception of health status, ambulatory ability,
and true cost of interventions to patient and soci-
ety.2-4 As technologic advances continue at a great
pace it is critical for vascular surgeons to lead with
regard to quality assessment and implementation of
new therapies.
EXISTING EFFORTS IN VASCULAR
SURGERY QUALITY ASSESSMENT
The four major themes of quality improvement
and quality assessment are methods and measures,
information technologies, organizational issues, and
the use of quality-related information.5 Vascular
Surgery as an entity has embraced several of these
aspects but has not followed through on others.
Methods and measures are embodied in the efforts
of the Society for Vascular Surgery and International
Society for Cardiovascular Surgery, North American
Chapter, to regulate reporting standards through ad
hoc committees for diagnostic-specific groups, and
regional societies have attempted to track individual
practices and surgery-specific outcomes through
registries, with which there has been admittedly poor
compliance. Organizational issues with regard to gov-
ernment agencies are well established in the advocacy
by the national societies with regard to the Resource
Based Relative Value system and the Health Care
Financing Administration’s recognition of the value of
certain new procedures and diagnostic tests. A quality
corollary to these lobbying efforts can be seen in the
efforts at granting appropriate accreditation to vascular
laboratories, endovascular efforts, and the certificate of
vascular qualifications. The penultimate example of
organizational efforts at quality control may be yet to
come in the establishment of a separate American
Board of Vascular Surgery.
We are lacking in the use of information tech-
nologies and the application of our analysis of qual-
ity issues. Whereas managed care organizations
maintain state-of-the-art relational databases and
also have a new capability of data warehousing,6 vas-
cular surgeons primarily follow the model of indi-
vidual practitioners whose data pools are only acces-
sible when multicenter studies are at play. Without
broad-based databases, we are unable to answer
many of the questions concerning our outcomes
that will prove critical to establishing the efficacy of
procedures and the long-term cost-effectiveness of
our proposed treatments for vascular diseases.
Lastly, we are lacking in quality measures for vas-
cular interventions. Our efforts have been directed
primarily to determining the mortality and morbidi-
ty data and technical options of specific procedures
or nonoperative therapies of conditions whose nat-
ural histories are often undefined. Vascular surgeons
have also attempted functional assessment of proce-
dure-specific metrics (e.g., limb salvage in infrain-
guinal disease)7 and systemic metrics8 (e.g., myocar-
dial infarction rates after aneurysm surgery). This is
not to belittle the importance of such measures, but
rather to serve as a reminder that limb salvage with-
out restored independence or aneurysm repair in an
octogenarian that results in a nursing home admis-
sion are the very issues, in addition to vascular dis-
ease–specific metrics, that we as a society (both
Vascular and American), must address.
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There are efforts in this direction. Interest in
appropriate screening intervals and size of interven-
tion for aortic aneurysms,9 the outcome of surgery
for the as-yet-undefined categories of symptomatic
carotid disease in the 50% to 70% deciles,10 as well as
independent studies on functional (health-assess-
ment based) analyses of vascular surgery proce-
dures11 are appearing in the surgical literature. Yet
the functional studies are few and far between and
are taking a back seat to the obviously important
natural history studies.
To recognize where the lack of information on
quality of life, general health, self perception, and
procedure-specific metrics can have a negative
impact on our patients and our society of vascular
surgeons, it is worth examining several examples.
Although infrainguinal bypass grafting for both clau-
dication and limb salvage is probably the most fre-
quently performed vascular procedure, we lack spe-
cific information that will be crucial in justifying the
performance of these procedures in the years to
come. There have been several reports that have
indicated that outcomes measures for general health,
for example the SF 36 form, can be used with some
validity; however, a definitive study has not been
conducted.11
Numerous examples of large series with excellent
short-term results and long-term patency rates can be
given to construct a supportive argument for contin-
uing an aggressive stance toward infrainguinal disease.
Some larger issues remain unaddressed. It has been
demonstrated that unsupervised exercise therapy
leads to much poorer outcomes than intervention for
occlusive disease in claudication.12 It also has been
suggested that a sedentary lifestyle is a previously
unrecognized and major contributing risk factor to
coronary events.13 Does this mean that we are failing
our patients by not taking a combined aggressive
approach to claudication and risk factor control and
that, in fact, our attitude to claudication in certain
subgroups is deleteriously unaggressive? An unwill-
ingness to assess the field in a broad-based health con-
text rather than a procedure-specific metric, in fact,
may be costing lives or hindering longevity.
Limb salvage, however, is pursued aggressively
because of issues ranging from the purported cost to
society of amputation and rehabilitation, patient
reluctance to accept an amputated limb, and quality
measures that suggest that self care, mobility, and
vaguely defined “lifestyle” issues all benefit by an
aggressive surgical stance. Reports exist, however,
that suggest that upwards of 22% of limb salvage
patients would be better served by amputation and
aggressive rehabilitation.14 In addition, in some
series, despite aggressive revascularization, amputa-
tion rates approached 35% at 1 year for patients with
critical ischemia.15 Others suggest that the mortality
rate of this patient group (42% at 3 years, with only
25% maintaining the index limb) does not justify the
procedure.16 The truth likely will lie somewhere
between these two views. We as a society of vascular
surgeons should be leading the charge to define the
subsets of patients who will benefit and the subsets
who won’t, as we enter an era of global caps on
health care dollars and assessment of technologies
on the basis of quality rendered and cost saved.
The flip side of improperly defining the right
candidates for aggressive therapies is exemplified by
the carotid surgery controversy of the late 1970s and
early 1980s. Carotid surgery fell into disfavor
because of published reports of high stroke rates
achieved by casual carotid surgeons and still-
unproved indications for carotid endarterectomy.17
A decline in the annual frequency of carotid
endarterectomy procedures from 170,000 to
approximately 85,000 in 1987 can be interpreted as
the missed opportunity to prevent 6000 to 8000
strokes that year alone. At costs to society estimated
at $30,000 to $150,000, the potential overall cost
approached $1 billion per year in 1987. Granted,
this is an analysis based on the assumption that all
carotid endarterectomy procedures that were not
performed would have been performed appropriate-
ly. However, the principle that early definition of the
validity of a technique can have enormous impact on
peoples’ health and social costs is still very much at
Fig. 1. Life cycle of medical technology.
play. As soon as technology is available to be studied
and either validated or not, it should be.
ASSESSMENT OF NEW VASCULAR 
TECHNOLOGIES
We are at an extremely exciting point in the
evolution of Vascular Surgery. Although besieged
by issues concerning reimbursement, control of the
clinical application of new technologies, and inde-
pendence as a specialty, we are also on the edge of
a revolution in the fashion in which vascular disease
is treated. Health care accounted for 20% of ven-
ture capital investments in 1997, and the prolifera-
tion of devices on the market promises to flood
surgeons with choices that we are ill-prepared to
make at present.
It is critical for us to focus on clinical outcomes.
Fig. 1 demonstrates the life cycle of new technology
in our society, referred to in health policy circles as
diffusion. The stages of technology acceptance are
introduction, take-off, maturation, and obsoles-
cence. At the point of maturation and subsequent
exponential dissemination, numerous forces are at
play. Ease of application, reduction in cost, patient
and referring physician demand (often uninformed),
and resultant market pressures can generate rapid
diffusion of techniques before validity is ensured.
Ease of technical intervention should not lead to
what can be termed indication creep. With a progres-
sive portion of surgical research funding coming from
industry rather than federal government, we must
ensure that assessment of new technologies addresses
both short-term efficacy and safety (necessary for
approval by the Food and Drug Administration) as
well as long-term benefit with regard to existing pro-
cedures and with regard to unfettered natural histories.
It is incumbent on vascular surgeons to demonstrate
for all future areas of new technology and potential
quality failure that cost is not a driver unless it is teth-
ered to quality. Improved quality with increased initial
expenditure can be cost-effective when viewed
through the lens of long-term outcomes and should
drive an effort to reduce ancillary variable costs associ-
ated with the procedure in question so that an advance
in quality is not sacrificed to budgetary concerns.
Endovascular aneurysm repair, carotid angioplasty,
stent-grafts for occlusive disease, minimally invasive
venous interventions, and new diagnostic tools should
all be included in this type of analysis and scrutiny.
SUMMARY
Vascular Surgery is poised at the edge of a rare
moment in medical care. Energy, intelligence, inno-
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vation, and resources are available to improve great-
ly the methods of vascular disease correction.
Precedent exists for the overzealous application of
technologies. Poor study design and inadequate
tracking of outcomes can dilute the value, discredit
a critical therapy, and undermine proper patient
selection.
The proper analysis of our new technologies will
be obtained only through well-organized studies,
information systems, and informed organizational
oversight. Our analysis must extend beyond proce-
dure-specific outcomes to include quality of life
issues measured in a validated and relevant fashion.
The present and future of vascular disease therapeu-
tics must reside under the control of those who have
devoted their lives to its theory and practice.
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